+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator



Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator



American Journal of Therapeutics 19(4): 261-268



A few observational studies have shown the protective effect of statins on preventing ventricular tachycardia/ventricular fibrillation (VT/VF). However, the disparate study results prompt further exploration of this concept. We performed a meta-analysis to assess whether statin therapy is associated with a decrease in the incidence or recurrence of VT/VF in patients with an implantable cardioverter-defibrillator (ICD).The MEDLINE(®) and Cochrane databases were searched from 1980 to July 2009 for studies examining the effect of statins on VT/VF in recipients of ICDs. We retrieved all prospective cohort studies that examined this association. The endpoint was defined as appropriate ICD therapy for VT/VF. The quality of individual studies was assessed using the Newcastle Ottawa Scale.Seven prospective cohort studies met our inclusion criteria with a total of 2278 patients with a mean follow-up of 19.7 months. Pooled analysis of the eligible studies revealed that statin therapy was associated with a 45% reduction in the risk of developing VT/VF in recepients of ICDs [pooled odds ratio (pOR): 0.55; 95% confidence interval: 0.34-0.90; heterogeneity I(2) = 81%, P = 0.02]. In a subgroup analysis, the magnitude of the risk reduction in patients with ischemic cardiomyopathy was 54% (pOR: 0.46, P = 0.05). Sensitivity analysis including studies with higher methodological qualities alone showed a significant protective effect (pOR: 0.48, P = 0.01). There was no evidence of publication bias in the analysis.Our meta-analysis suggests an association between the use of statin and a reduction in the VT/VF occurrence in recipients of ICDs, mainly in patients with ischemic cardiomyopathy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911304

Download citation: RISBibTeXText

PMID: 21048429

DOI: 10.1097/MJT.0b013e3181f94c38


Related references

Early statin therapy reduces risk of ICD shocks in patients with an implantable cardioverter-defibrillator undergoing ablation for ventricular tachycardia. 2007

Statin therapy reduces the risk of shock from an implantable cardioverter-defibrillator. Circulation 108(17 Supplement): IV-543, October 28, 2003

Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. American Journal of Cardiology 95(4): 490-491, 2005

Impact of accelerated ventricular tachyarrhythmias on mortality in patients with implantable cardioverter-defibrillator therapy. International Journal of Cardiology 167(6): 3006-3010, 2014

Comparison of age (<75 Years versus ≥75 Years) to risk of ventricular tachyarrhythmias and implantable cardioverter defibrillator shocks (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). American Journal of Cardiology 114(12): 1855-1860, 2015

Prophylactic automatic implantable cardioverter-defibrillator patches in patients at high risk for postoperative ventricular tachyarrhythmias. Journal of the American College of Cardiology 13(6): 1367-1373, 1989

Do statins reduce the risk of atrial fibrillation/flutter or ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator?. 2007

Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter-defibrillator discharge in patients with ventricular tachyarrhythmias. American Journal Of Cardiology. 73(9): 683-687, 1994

Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention. Yearbook of Cardiology 2012: 478-480, 2012

Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. Journal of the American College of Cardiology 58(14): 1485-1496, 2011

Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm 9(2): 217-224.E2, 2013

Polymorphisms associated with ventricular tachyarrhythmias: rationale, design, and endpoints of the 'diagnostic data influence on disease management and relation of genomics to ventricular tachyarrhythmias in implantable cardioverter/defibrillator patients (DISCOVERY)' study. Europace 12(3): 424-429, 2010

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. Journal of Cardiovascular Pharmacology and Therapeutics 15(1): 37-40, 2010

Ventricular tachycardia induced by implantable cardioverter defibrillator therapy for supraventricular tachyarrhythmias. European Heart Journal 14(ABSTR SUPPL ): 371, 1993

Non-pharmacological therapy in life-threatening ventricular tachyarrhythmias: Automatic implantable cardioverter defibrillator. Intensivmedizin und Notfallmedizin 29(7): 365-370, 1992